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Nasal powder systemCo-grinding is a procedure for the preparation of nanoparticles in which the drug is ground together with one
or more excipients. The grinding of meloxicam, a crystalline solid, together with amorphous polyvinylpyrro-
lidone (PVP) or semi-crystalline polyethylene glycol (PEG) as excipients, is expected to lead to a drastic
reduction in particle size. We optimized meloxicam grinding using a three level full factorial response surface
design. In the case of PVP the optimum co-grinding parameter set in our study proved to be a meloxicam to
PVP-C30 ratio of 1:1, and a rotation frequency of 400 rpm. The best size reduction was achieved at a
meloxicam to PEG 6000 ratio=1:2 at a rotation frequency of 400 rpm: nanoparticles averaging
dSEM=174 nm in diameter and with a very narrow size distribution (standard deviation 35% of mean)
were obtained. X-ray powder diffraction analysis indicated that the optimized products contained amorphous
meloxicam nanoparticles in the PVP-C30 composition, although meloxicam nanocrystals could also be
detected in the samples which contained PEG 6000. The dissolution properties were significantly increased
under nasal conditions (pH 5.1, temperature 30 °C), especially in the case of the amorphous product. Such dry
powder systems can offer novel opportunities in systemic nasal drug delivery.zeged, Hungary. Tel.: +36 62
ó-Révész).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Nanonization offers an excellent possibility to overcome mucosal
barriers [1,2] and has several advantages in drug delivery [3,4]. It is
believed that nanoparticles can be transported across barriers into the
bloodstream without prior dissolution [5]. Nano-sized drugs with
carriers can overcome the resistance offered by the physiological
barriers in the body because the efficient delivery of drugs to various
parts of the body is directly affected by the particle size [6].
Several techniques are available for the production of drug
nanoparticles [7]. Basically, bottom-up and top-down technologies
can be differentiated. The bottom-up technologies start from the
molecules, which are precipitated (crystallized) in a controlled fashion
to yield the desired particle size. Nowadays, bottom-up techniques are
not the main choice for drug nanoparticle production due to the use of
organic solvents. The top-down technologies are disintegration
methods e.g. various types of milling (high-intensity ultrasonication,
high-pressure homogenization, grinding or co-grinding) are more
frequently used [8].
The size reduction of pharmaceutical materials is often performed
by means of dry milling [9,10], but the size reduction possible by drymilling is known to be limited to around 3 μm due to aggregation of
the particles. Experiments focusing on a particle size reduction to the
submicron region by co-grinding with additives have recently been
attempted [11–14].
Nanonization has become a popular approach to produce particles
in the size range of 200–400 nm, to improve both the dissolution rate
and the solubility of the compound [15]. The latter phenomenon is
due to the well-known dependency of solubility on particle size as
described by the Ostwald–Freundlich equation. Breakage of micron-
sized drug crystals into nanoparticles creates an increased particle
surface area, which is thermodynamically unfavorable. Thus, nano-
sized particles tend to agglomerate to reduce their surface area.
Particle agglomeration can be prevented by steric stabilization using
polymeric excipients [16].
Co-grinding is a top-down disintegration procedure for the
preparation of nanoparticles by grinding of the drug together with
one or more excipients [17,18]. A main advantage of co-grinding as
compared to other methods is that it is a simple procedure and organic
solvents are not needed for the preparation of nanoparticles; it is
therefore an economically and environmentally desirable technology
[19]. It is important to control the parameters (e.g. duration of grinding,
the grinding rate, the material and the volume of the grinding pot, the
material and the number of the grinding balls, the grinding excipients
and the drug/excipient ratio) by means of a factorial experimental
design [20,21].
Table 1
General parameters of co-grinding, independent variables.
Material of the grinding pot Si3N4
Material of the grinding balls Si3N4
Number of the grinding balls 25
Vgrinding pot 80 mL
Dgrinding ball 10 mm
tmilling 2 h
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water-insoluble drug (NSAID), is an enolic acid oxicam derivative
[22,23]. The single oral dose of meloxicam is 7.5–15 mg. The favorable
side-effect profile and the low quantity of a single dose make this
NSAID suitable for administration via alternative pathways, e.g.
intranasally. This may result in novel opportunities for the easing of
pain, which affects the region of the head.
A reduction of the particle size of meloxicam into the nano-size
range (100–1000 nm) is possible by crystallization methods through
formulation of the drug in a nanosuspension [24]. However, co-
grinding offers a simpler and environmentally friendly way of
preparing meloxicam nanoparticles. Nanoparticles are a formulation
principle for all poorly soluble drugs for which the dissolution velocity
is the rate limiting step for absorption and thus the reason for a too
low bioavailability. The increase in surface area leads to an increase in
the dissolution velocity.
Water-soluble polymers have typically been used as co-grinding
excipients [13,25,26]. An example is polyvinylpyrrolidone (PVP), an
amorphous excipient which does not melt during the grinding process
therefore it could also help particle size reduction and to prevent the
agglomeration, as stabilizer agent [27–29]. On the contrary, polyethylene
glycol (PEG) is a semicrystallinegrindingexcipientwith lowmeltingpoint
which couldmelt due to frictionwork andas a consequence it cannot help
as efficiently as PVP the size reduction.
The grinding of meloxicam, a crystalline solid, together with
amorphous PVP or semicrystalline PEG as excipients is expected to
lead to a drastic reduction in particle size and to possible changes in
the crystallinity of meloxicam without any harmful alterations in its
pharmaceutical effect. The crystalline and the amorphous form of an
active agent have no difference in their effect, although the onset of
action can be improved with faster dissolution rate.
Multivariate problems similar to meloxicam grinding are often
optimized by using the COST (Change One Separate factor at a Time)
approach: all parameters but one are fixed, and the response of the
system is studied as a function of the changing variable. Each variable
is scanned in this way, and the combination of their optimum values is
accepted as the overall optimum. Unfortunately, this method is slow,
since the number of necessary experiments increases considerably
with the number of variables. Moreover, the COST approach can
seldom find the true overall optimum of a system since it assumes that
the effects of all variables are completely independent, whereas the
response of a real system to change in any single parameter often
appears as the overall effect of several parameter alterations (i.e. real-
life multidimensional parameter spaces are seldom orthogonal). A
good strategy for finding the overall optimum of a multivariate
problem is to fit the response surface on the basis of the responses
obtained from well-chosen parameter sets. Since the effect of any
single variable can usually be accounted for by a second-order
polynomial, it is customary to test parameters at three different levels:
a high, a medium and a low setting. Such designs, called three-level
full factorial designs, have been applied successfully in the past to
optimize the synthesis of carbon nanotubes [20,30], the deposition of
titanate nanowires on glass [31] and the wet peroxidation of aqueous
phenol solution [32]. The simplest three-level full factorial design is to
pick three values for one independent variable (x1: rotation speed),
chart the three corresponding response (d: particle diameter) values
in a standard two dimensional Cartesian coordinate system and fit the
d=f(x1) function by a parabola. In case of two independent variables
(x1: rotation speed and x2: meloxicam to excipient ratio) we need to
sample 3×3=9 points in the x1x2 plane and chart the corresponding
d values as elevation above the x1x2 plane in a three dimensional
coordinate system.
The aim of our present research work was to produce meloxicam
nanoparticles by co-grinding process with PVP and PEG, investigating
the influence of different parameters on particle size and optimizing
them by using a three-level full factorial design so that nano-sizedmeloxicam particles of uniform size distribution are obtained. The
optimized products were investigated from the aspects of crystallinity
and extent of dissolution under in vitro nasal circumstances.
2. Materials and methods
2.1. Materials
Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-
benzothiazine-3-carboxamide-1,1-dioxide) was obtained from EGIS
Ltd. (Budapest, Hungary). The grinding additives, polyvinylpyrroli-
done (PVP) K25 and C30 were purchased from BASF (Ludwigshafen,
Germany). Types of PVP (K25 and C30) differ in molecular weight,
viscosity and field of application. Molecular weight of PVP-K25 is
about 34,000 and PVP-C30 has a higher molecular weight (about
58,000). Because their viscosity relating to molecular weight so the
viscosity of PVP-C30 is higher, than for K25. In the case of PVP the
letter “C” indicates applicability also for preparation of aseptic dosage
forms. Polyethylene glycol (PEG) 6000 and 20,000 were from Sigma-
Aldrich Chemie GmbH, Germany. The numbers of PEG (6000 and
20,000) refer to the molecular weight of the polymer.
2.2. Methods
2.2.1. Preliminary experiments
Several pharmaceutical excipients were tested, and the results of
the co-grinding of meloxicam with PVP and PEG were the most
promising in the aspect of particle size reduction. In these preliminary
experiments some optimum parameters of the grinding (the duration
of grinding, the material and the volume of the grinding pot and the
material and the number of grinding balls) were also set.
2.2.2. Preparation of co-ground formulations and their physical mixtures
Binarymixtures of as-receivedmeloxicam powder and the carriers
PVP-C30, PVP-K25, PEG 6000 and PEG 20,000 were mixed and
charged into the chamber of the planetary monomill (Fritsch
Pulverisette 6, Fritsch GmbH, Idar-Oberstein, Germany) in various
drug-carrier ratios (1:0.5, 1:1 and 1:2). The grindingwas performed in
an 80 cm3 silicon nitride (Si3N4) milling drum containing 25 silicon
nitride balls 10 mm in diameter. In each experiment, 1.0 g of
meloxicam was ground together with the calculated amount of
polymer additive.
The milling parameters are given in Table 1 and the investigated
parameters are listed in Table 2. After grinding, the samples were
stored in plastic vials until use.
The physical mixtures of drug-carrier were prepared by accurately
weighing the calculated amounts of meloxicam and carrier, mixing
them well in a porcelain mortar and storing in plastic vials until use.
2.2.3. Determination of particle size by scanning electron microscopic
image analysis
2.2.3.1. Scanning electron microscopy (SEM). Co-ground products were
washed and centrifuged three times in distilled water to separate the
water-soluble excipient from the water-insoluble meloxicam (the
solubility of meloxicam is 4.4±0.7 μg/mL [24]), so that individual
meloxicam particles could be studied. The particle size and the surface
Table 2
Compositions of different samples, parameters of optimization.
Meloxicam/excipient ratio 1:0.5, 1:1, 1:2
Excipients PVP-C30, PVP-K25, PEG 6000, PEG 20,000
Revolutions per minute (rpm) 200, 300, 400
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Samples were fixed onto ametallic stub with double-sided conductive
tape (diameter 12 mm, Oxon, Oxford Instruments, UK). Images were
taken in secondary electron image mode on a Hitachi S-4700 Type II
instrument at an acceleration voltage of 10 kV.
2.2.3.2. Image analysis. Meloxicam particle diameter distributions
were obtained by analyzing several SEM images with the ImageJ
software environment [33]. Over 150 individual particle measure-
ments were made in at least five different images in order to
determine the particle size accurately. Although less frequently used
than TEM or dynamic light scattering, SEM image analysis is an
established method for nanoparticle size analysis: for instance, it was
applied successfully for the characterization of carbon nanotube
networks [30], Zn-glycerolate microstacks [34] and co-grinding
products of PVP and CaCO3 [35].
2.2.3.3. Design of experiments. In a series of pre-screening experiments
the following parameters were fixed (see Table 1): (i) the milling
drum size and material, (ii) the ball size and number, and (iii) the
milling duration. The remaining variables, i.e. the excipient type, the
excipient-to-meloxicam ratio and the milling rate were the param-
eters featuring in the optimization. A full factorial design plan was
created and carried out with the meloxicam particle size distribution
defined as response factor. All calculations were performed by using
Minitab 14 (Minitab Statistical Software).Fig.1. Scanning electronmicroscopic images frommeloxicam before grinding (A), after co-gr
at 400 rpm (C), with PEG 6000 in a ratio of 1:0.5 at 400 rpm (D)/from all of the products
particles/.2.2.4. Further investigations of the optimized products
2.2.4.1. X-ray powder diffraction analysis (XRPD). The physical state of
meloxicam in the different samples was evaluated by XRPD.
Diffraction patterns were analyzed with a Miniflex II X-ray Diffrac-
tometer (Rigaku Co. Tokyo, Japan), where the tube anode was Cu with
Kα=1.5405 Å. The pattern was collected with a tube voltage of 30 kV
and a tube current of 15 mA in in-step scan mode (4°/min). The
instrument was calibrated by using Si.
2.2.4.2. Studies of the extent of dissolution under in vitro nasal
conditions. The dissolution of different powder samples containing the
same amount of drug (10 mg) was determined according to the
European Pharmacopoeia (6th Edition) paddle method (Pharma test,
Heinburg, Germany), which means a rotating paddle in the dissolution
vessel. 50.0 mLof phosphate buffer solution (pH5.6±0.1) at 30±0.5 °C
was used as a dissolutionmediumand the rotation speed of the paddles
was 100 rpm. At predetermined times, 1 mL samples were withdrawn
and immediately filtered (cut-off 0.2 μm, Minisart SRP 25, Sartorius,
Germany) and the amount of dissolved drug was determined
spectrophotometrically (λ=364 nm). Withdrawn samples were
replaced with 1 mL of fresh medium.
3. Results and discussion
Fig. 1 presents typical SEM images of meloxicam particles before
grinding (A) and after grinding in the presence of the various
excipients (B–D). The particle size was reduced by roughly one order
of magnitude, regardless of the additive used. This primary effect
originated from the high-energy collisions taking place in the
planetary ball mill [36]. Ball milling is a process with complex
mechanics, analyzed in detail by Chattopadhyay et al. [37]. On the
basis of their model, it was possible to calculate the energetics of the
co-grinding experiments performed. The results in Table 3 indicateinding with PVP-K25 in a ratio of 1:0.5 at 300 rpm (B), with PEG 20,000 in a ratio of 1:0.5
PVP and PEG were dissolved by distilled water due to the visualization of meloxicam
Table 3
Milling energetics map of the experiments performed.
Cumulative collision energy transferred
(kJ· g−1)





No additive 1:0.5 1:1 1:2
200 240 8.56 5.71 4.28 2.85
300 360 28.89 19.27 14.45 9.63
400 480 68.50 45.67 34.25 22.83
Table 4
Particle diameter (dSEM) of meloxicam particles in different compositions.
Excipient Meloxicam/excipient ratio Rotation speed (rpm) dSEM±SD (nm)
– 1:0 – 2643.6±2629.1
– 1:0 200 364.5±228.1
– 1:0 300 275.0±170.6
– 1:0 400 343.5±205.9
PVP-C30 1:0.5 200 511±333
PVP-C30 1:1 200 267±158
PVP-C30 1:2 200 221.7±105.4
PVP-C30 1:0.5 300 243±115
PVP-C30 1:1 300 242±141
PVP-C30 1:2 300 302.3±115.7
PVP-C30 1:0.5 400 209.9±85.3
PVP-C30 1:1 400 140.4±69.2
PVP-C30 1:2 400 238.6±147.9
PVP-K25 1:0.5 200 203.6±190.0
PVP-K25 1:1 200 192.7±74.4
PVP-K25 1:2 200 229.1±203.2
PVP-K25 1:0.5 300 266.3±117.0
PVP-K25 1:1 300 351.7±227.7
PVP-K25 1:2 300 277.6±139.9
PVP-K25 1:0.5 400 251.5±362.6
PVP-K25 1:1 400 246.4±108.5
PVP-K25 1:2 400 262.8±124.7
PEG 6000 1:0.5 200 175.2±57.4
PEG 6000 1:1 200 212.3±92.0
PEG 6000 1:2 200 -
PEG 6000 1:0.5 300 165.0±59.6
PEG 6000 1:1 300 204.4±88.9
PEG 6000 1:2 300 358.1±145.3
PEG 6000 1:0.5 400 197.3±84.8
PEG 6000 1:1 400 229.5±92.3
PEG 6000 1:2 400 173.8±60.3
PEG 20,000 1:0.5 200 368.7±238.0
PEG 20,000 1:1 200 318.8±136.2
PEG 20,000 1:2 200 200.0±134.6
PEG 20,000 1:0.5 300 235.5±117.7
PEG 20,000 1:1 300 217.6±103.7
PEG 20,000 1:2 300 -
PEG 20,000 1:0.5 400 185.1±73.7
PEG 20,000 1:1 400 234.5±122.9
PEG 20,000 1:2 400 333.8±151.0
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via collisions in our system lies in the range of 2.80–68.50 kJg−1.
A closer analysis of the SEM micrographs revealed that there were
considerable differences in nanoparticle size distribution as a function
of the excipient type used. The size distribution function is
characterized by the mean particle diameter and the standard
deviation of the diameter (given as a percentage of the mean and
denoted as SD%). These values are reported in Table 4, and their
relationship with the grinding variables is analyzed quantitatively
in the main effects plots (Figs. 2 and 3) and interaction plots (Figs. 4
and 5). The main effects plot shows the average response for each
value of each variable, combining the effects of the other variables as if
all variables were independent. The main effects plots for the
meloxicam particle diameter indicate that the tested excipients can
all promote size reduction (Fig. 2). Increasing the relative amount of
meloxicam in the system resulted in larger product particles, whereas
increasing themilling energy (grinding rate) reduced the particle size.
Since our goal was to grind meloxicam into uniformly small particles
so that its administration can be controlled, it was important to study
the main effects plots characterizing the broadness of the particle size
distribution curve (SD%) (Fig. 3). It is evident from Fig. 3 that the
excipients PVP-K25 and PEG 6000 provide significantly broader and
narrower diameter distributions, respectively, than the other two
tested additives. Increase of the meloxicam to additive ratio resulted
in a less uniform product. On the other hand, the distribution
uniformity as a function of the milling energy exhibited a minimum at
300 rpm.
Interaction plots illustrate the effects between variables, which are
not independent by showing themeans of the responses for each level
of a factor for each level of a second factor pairwise for all factors
involved in the study. Therefore, the interaction plots presented in
Figs. 4 and 5 for the mean diameter and the SD%, respectively, can be
used to gain insight into the complex interactions between the
grinding parameters. For example: (i) all additives but PVP-C30 result
in a particle diameter increase at higher milling rates, (ii) increasing
the milling frequency can compensate the diameter differences
introduced by changing the meloxicam to additive ratio, (iii) the use
of PEG 6000 as additive results in particularly narrow size distribu-
tions, regardless of the choice of the other two parameters, etc.
We are now in a position to summarize the grinding behavior of
the novel NSAID meloxicam in a high-energy ball mill with Si3N4 as
grinding material. In the absence of any grinding additives, the final
product particles are too large at low milling energy (dSEM=364 nm
at 200 rpm) and aggregate rapidly at high energy (dSEM=343 nm at
400 rpm). There is an optimum at 300 rpm. However, even at this
setting, the average product particle size is above dSEM=270 nm. It is
interesting to note that, without additives, the relative broadness of
the particle size distribution function was independent of the milling
energy (SD~61%).
With PVP-C30, it was possible to push the average meloxicam
particle size below 250 nm and the average SD below 50%. This was a
significant improvement relative to the additive-free grinding result.
The optimum co-grinding parameter set for PVP-C30 was a melox-
icam to excipient ratio=1:1, and a rotation frequency of 400 rpm.If the target drug administration task allows the application of
PEG 6000 as additive, then it is possible to improve the co-grinding
process further. The parameter setting meloxicam to PEG 6000=1:2
at a rotation frequency of 400 rpm yields nanoparticles averaging
dSEM=174 nm in diameter and a very narrow size distribution,
characterized by SD=35%. This set is the overall optimum result in
our study.
The most promising products of the co-grinding process were
further investigated by XRPD analysis. The optimized products
(Table 5, Fig. 6) differ in their crystallinity, which can be observed
in the diffraction spectra (Fig. 7). The XRPD patterns of meloxicam,
physical mixtures and products containing meloxicam and excipients
in the optimized ratio are presented. The presence of numerous
distinct peaks in the XRPD spectrum indicates that meloxicam is a
crystalline material; its characteristic peaks appear at diffraction
angles 2Θ of 13.22, 15.06, 26.46 and 26.67°. The crystallinity of
meloxicam was decreased in the co-grinding process with PVP-C30;
in the other optimized product, which contains PEG 6000 the
crystallinity of meloxicam did not change significantly comparing to
the physical mixture. The crystalline meloxicamwas altered in the co-
grinding process with the amorphous excipient, PVP-C30, leading to
amorphous nanoparticles. With PEG 6000 as excipient, the crystal-
linity of meloxicam was proved (Fig. 7), i.e. meloxicam nanocrystals
were prepared.
The extent of dissolution was determined under conditions of
nasal drug delivery (Fig. 8). Under in vitro circumstances, we
attempted to mimic the physiological conditions of the human
nose; the temperature of the dissolution medium was 30 °C and the
Fig. 2. Influence of different parameters (main effects plot, data means) onmeloxicam crystal diameter (C30=PVP-C30, K25=PVP-K25, PEG20k=PEG 20,000, PEG6k=PEG 6000).
Fig. 3. Main effects plot (data means) for SD% (C30=PVP-C30, K25=PVP-K25, PEG20k=PEG 20,000, PEG6k=PEG 6000).
Fig. 4. Interaction plot (data means) for diameter (C30=PVP-C30, K25=PVP-K25, PEG20k=PEG 20,000, PEG6k=PEG 6000).
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Fig. 5. Interaction plot (data means) for SD% (C30=PVP-C30, K25=PVP-K25, PEG20k=PEG 20,000, PEG6k=PEG 6000).
Table 5
Optimized products.
Grinding excipient of meloxicam Drug to excipient ratio Rotation speed (rpm)
PVP-C30 1:1 400
PEG 6000 1:2 400
215L. Kürti et al. / Powder Technology 212 (2011) 210–217pH was 5.6. These conditions alter the dissolution properties of the
effective agent: lower temperature and pH decreases the extent of
meloxicam dissolution, although the particle size reduction enhances
the extent of dissolution. In the meloxicam PVP-C30 composition, the
extent of dissolution after 60 min increased in case of the co-ground
product from 4.1±0.21% to 66.2±4.73% relative to the physical
mixture of the effective agent and the excipient. In the background of
this phenomenon stands in one hand the reduction of the particle size
(nanonization) and on the other hand the decrease in crystallinity of
the effective agent (amorphization). Nanoparticles improve dissolu-
tion rate and bioavailability of poorly water-soluble drugs [38–41]
owing to increased surface area available for dissolution as described
by the Noyes–Whitney equation [42]. The co-grinding technique has
already been employed for amorphization of drugs [43,44].
A two-fold enhancement of the extent of meloxicam dissolution
was observed in the case of the meloxicam PEG 6000 co-ground
product, in which meloxicam is in nanocrystal form. By now, main
attentionwas focussed on size and related surface area. It was recently
reported that the interfacial reaction resistance is getting the velocity
determining parameter for crystals below 1 μm. Design of nanocrys-Fig. 6. Scanning electron microscopic images from the optimized products: meloxicam after
with PEG 6000 in a ratio of 1:2 at 400 rpm (B)/from all of the products PVP and PEG weretals with faster interfacial reaction can further enhance the dissolution
velocity [45]. In addition, nanomaterials possess improved adhesive-
ness to biological membranes [7]. The extent ofmeloxicam dissolution
after 60 min in the physical mixture was 4.1±0.21%, while that for
the optimized product was 8.3±0.08%. In the physical mixtures the
excipient had no influence on the extent of meloxicam dissolution,
contrary products, which were undergone nanonization with co-
grinding process, showed significantly higher extent of dissolution.
Nanonization and amorphization of meloxicam resulted in
significantly better dissolution properties in the in vitro dissolution
studies under conditions, which mimic the physiological pH and
temperature of the human nose.
Insoluble powders are likely to be effective for nasal systemic drug
delivery [46]. The nasal powder formulations enhance systemic
bioavailability, and are superior to liquid formulations [47,48] from
the aspects of increased chemical stability of the drug, no requirement
for preservatives in the formulations, and the feasibility of adminis-
tering relatively large amounts of drug [49–51].
4. Conclusions
This study explored the effects of additives on the co-grinding
behavior of the frequently applied NSAID meloxicam in a high-energy
planetary ball mill. It was shown that both PVP and PEG as additives
can act as efficient excipients in the mechanical size reduction of
meloxicam particles. The influence of the grinding parameters:
additive type, meloxicam to additive ratio and milling frequency on
the product particle size distribution function was studied via a fullco-grinding with PVP-C30 in a ratio of 1:1 at 400 rpm (A), meloxicam after co-grinding
dissolved with distilled water due to the visualization of meloxicam particles/.
Fig. 7. X-ray powder diffraction spectra of meloxicam (5), physical mixtures (4, 3) and
products of meloxicam co-grinded with PVP-C30 (2), meloxicam with PEG 6000 (1).
216 L. Kürti et al. / Powder Technology 212 (2011) 210–217factorial design. Optimum grinding parameter sets for the nitrogen-
containing additive PVP (meloxicam to PVP-C30 ratio=1:1, rotation
frequency 400 rpm) and for nitrogen-free PEG 6000 (meloxicam to
PEG 6000=1:2, rotation frequency 400 rpm) were identified.
XRPD analysis indicated that the optimized products contained
amorphous meloxicam nanoparticles in the PVP-C30 composition,
although meloxicam nanocrystals could be detected in the samples
which contained PEG 6000. The dissolution properties are also
significantly increased under nasal conditions (pH 5.1, temperature
30 °C), especially in the case of the amorphous product. These dry
powder systems can offer novel opportunities in systemic nasal drug
delivery.
These products are suitable for further investigations in in vitro cell
culture models, in ex vivo tissue models and in in vivo animal
experiments with the aim of intranasal systemic drug delivery.Fig. 8. The extent of meloxicam dissolution in the optimized products and in the
physical mixtures, dissolution circumstances: pH 5.6±0.1, 30±0.5 °C.Acknowledgement
This work was supported by the TÁMOP research project TÁMOP-
4.2.1/B-09/1/KONV-2010-0005 and the OTKA-NNF 78920 project.References
[1] M.J. Alonso, Nanomedicines for overcoming biological barriers, Biomed. Pharmac-
other. 58 (2004) 168–172.
[2] A. Graf, E. Ablinger, S. Peters, A. Zimmer, S. Hook, T. Rades, Microemulsions
containing lecithin and sugar-based surfactants: nanoparticle templates for
delivery of proteins and peptides, Int. J. Pharm. 350 (2008) 351–360.
[3] W.H. De Jong, P.J.A. Borm, Drug delivery and nanoparticles: applications and
hazards, Int. J. Nanomed. 3/2 (2008) 133–149.
[4] H. Chen, C. Khemtong, X. Yang, X. Chang, J. Gao, Nanonization strategies for poorly
water-soluble drugs, Drug Discov. Today (2010), doi:10.1016/j.drudis.2010.02.009.
[5] J. Brooking, S.S. Davis, L. Illum, Transport of nanoparticles across the rat nasal
mucosa, J. Drug Target 9 (2001) 267–279.
[6] M. Rawat, D. Singh, S. Saraf, Nanocarriers: promising vehicle for bioactive drugs,
Biol. Pharm. Bull. 29/9 (2006) 1790–1798.
[7] R. Shegokar, R.H. Müller, Nanocrystals: industrially feasible multifunctional
formulation technology for poorly soluble actives, Int. J. Pharm. 399 (2010)
129–139.
[8] C.M. Keck, R.H. Müller, Drug nanoparticles of poorly soluble drugs produced by
high pressure homogenisation, Eur. J. Pharm. Biopharm. 62 (2006) 3–16.
[9] O.d. Vegt, H. Vromans, J.d. Toonder, K.v.d.V. Maarschalk, Influence of flaws and
crystal properties on particle fracture in a jet mill, Powder Technol. 191 (2009)
72–77.
[10] G. Delagrammatikas, M. Delagrammatikas, S. Tsimas, Particle size distributions a
new approach, Powder Technol. 176 (2007) 57–65.
[11] H. Kubo, T. Osawa, K. Takashima,M.Mizobe, Enhancement of oral bioavailability and
pharmacological effect of by micronization in co-ground mixture with d-mannitol,
Biol. Pharm. Bull. 19 (1997) 741–747.
[12] G.G. Liversidge, K.C. Cundy, Particle size reduction for improvement of oral
bioavailability of hydrophobic drugs: absolute oral bioavailability of nanocrystal-
line danazol in beagle dogs, Int. J. Pharm. 125 (1995) 91–97.
[13] M. Sugimoto, T.S. Okagaki, S. Narisawa, Y. Koida, K. Nakajima, Improvement of
dissolution characteristics and bioavailability of poorly water-soluble drugs by
novel cogrinding method using water-soluble polymer, Int. J. Pharm. 160 (1998)
11–19.
[14] T. Yamada, N. Saito, T. Imai, M. Otagiri, Effect of grinding with hydroxypropyl
cellulose on the dissolution and particle size of a poorly water-soluble drug,
Chem. Pharm. Bull. 47 (1999) 1311–1313.
[15] G:G. Liversidge, K.C. Cundy, J. Bishop, D. Czekai, Surface modified drug
nanoparticles, US Patent (1992) 5,145,684.
[16] B.E. Rabinow, Nanosuspensions in drug delivery, Nat. Rev. Drug Discov. 3 (2004)
785–796.
[17] K. Moribe, A. Pongpeerapat, Y. Tozuka, K. Yamamoto, Drug nanoparticle formation
from drug/HPMC/SDS ternary ground mixtures, Pharmazie 61 (2006) 97–101.
[18] C. Zapata, C. Frances, N. Le Bolay, S. Molina-Boisseau, Production of small
composite particles by co-grinding in a media mill. Characterization of the
granulometric and themechanical properties, Trans. IChemE, Part A, Ch. E. R. D. 82
(A5) (2004) 631–636.
[19] M. Barzegar-Jalali, H. Valizadeh, M.-R. Siahi Shadbad, K. Adibkia, G. Mohammadi,
A. Farahani, Z. Arash, A. Nokhodchi, Cogrinding as an approach to enhance
dissolution rate of a poorly water-soluble drug (gliclazide), Powder Technol. 197
(2010) 150–158.
[20] Á. Kukovecz, D. Méhn, E. Nemes-Nagy, R. Szabó, I. Kiricsi, Optimization of CCVD
synthesis conditions for single-wall carbon nanotubes by statistical design of
experiments (DoE), Carbon 43 (2005) 2842–2849.
[21] S.L.A. Hennart, M.C. Domingues, W.J. Wildeboer, P. van Hee, G.M.H. Meesters,
Study of the process of stirred ball milling of poorly water soluble organic
products using factorial design, Powder Technol. 198 (2010) 56–60.
[22] M. Fahmy, Ca-alginate beads loaded with meloxicam: effect of alginate chemical
composition on the properties of the beads and ulcerogenicity of the drug, J. Drug
Del. Sci. Technol. 16 (2006) 183–189.
[23] G. Hanft, D. Turck, S. Scheuerer, R. Sigmund, Meloxicam oral suspension: a
treatment alternative to solid meloxicam formulations, Inflamm. Res. 50 (2001)
35–37.
[24] R. Ambrus, P. Kocbek, J. Kristl, R. Sibanc, R. Rajkó, P. Szabó-Révész, Investigation of
preparation parameters to improve the dissolution of poorly water-soluble
meloxicam, Int. J. Pharm. 381 (2009) 153–159.
[25] M. Jafar, M.H.G. Dehgan, A. Shareef, Enhancement of dissolution and antiinfam-
matory effect of meloxicam using solid dispersions, Int. J. App. Pharm. 2/1 (2010)
22–27.
[26] T.P. Shakhtshneider, M.A. Vasiltchenko, A.A. Politov, V.V. Boldyrev, The mecha-
nochemical preparation of solid disperse systems of ibuprofen–polyethylene
glycol, Int. J. Pharm. 130 (1996) 25–32.
[27] K. Ioth, A. Pongpeerapat, Y. Tozuka, T. Oguchi, K. Yamamoto, Nanoparticle
formation of poorly water-soluble drugs from ternary ground mixtures with PVP
and SDS, Chem. Pharm. Bull. 51 (2) (2003) 171–174.
[28] L.S. Taylor, G. Zografi, Spectroscopic characterization of interactions between PVP
and indomethacin in amorphous molecular dispersion, Pharm. Res. 14 (1997)
1691–1698.
217L. Kürti et al. / Powder Technology 212 (2011) 210–217[29] T. Watanabe, S. Hasegawa, N. Wakiyama, A. Kusai, M. Senna, Comparison between
polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a
solid state dispersion, Int. J. Pharm. 250 (2003) 283–286.
[30] R. Smajda, Á. Kukovecz, Z. Kónya, I. Kiricsi, Structure and gas permeability of
multi-wall carbon nanotube buckypapers, Carbon 45/6 (2007) 1176–1184.
[31] M. Daranyi, Á. Kukovecz, E. Horváth, Z. Kónya, I. Kiricsi, Fine tuning the coverage of
a titanate nanowire layer on a glass substrate, Chem. Phys. Lett. 460 (1–3) (2008)
191–195.
[32] J.A. Melero, G. Calleja, F. Martinez, R. Molina, M.I. Pariente, Nanocomposite Fe2O3/
SBA-15: an efficient and stable catalyst for the catalytic wet peroxidation of
phenolic aqueous solutions, Chem. Eng. J. 131 (1–3) (2007) 245–256.
[33] M.D. Abramoff, P.J. Magelhaes, S.J. Ram, Image processing with image, J.
Biophotonics Int. 11/7 (2004) 36–42.
[34] R. Remias, Á. Kukovecz, M. Daranyi, G. Kozma, S. Varga, Z. Kónya, I. Kiricsi, Zn-
glycerolate microstacks, Eur. J. Inorg. Chem. 24 (2009) 3622–3627.
[35] C. Zapata-Massot, C. Frances, N. Le Bolay, On the use of scanning electron
microscopy for the modelling of co-grinding kinetics in a tumbling ball mill,
Powder Technol. 143–144 (2004) 215–229.
[36] J. Alkebro, S. BeHgin-Colin, A. Mocellin, R. Warren, Modeling high-energy ball
milling in the alumina–yttria system, J. Solid State Chem. 164 (2002) 88–97.
[37] P.P. Chattopadhyay, I. Manna, S. Talapatra, S.K. Pabi, A mathematical analysis of
milling mechanics in a planetary ball mill, Mater. Chem. Phys. 68 (2001) 85–94.
[38] R.H. Muller, A. Akkar, Drug nanocrystals of poorly soluble drugs, in: J.A. Schwarz,
C. Contescu, K. Putyera (Eds.), Encyclopedia of Nanoscience and Nanotechnology,
Marcel Dekker, New York, 2004, pp. 627–638.
[39] V.B. Patravale, A.A. Date, R.M. Kulkarni, Nanosuspensions: a promising drug
delivery strategy, J. Pharm. Pharmacol. 56 (2004) 827–840.
[40] M. Mosharraf, C. Nystrom, The effect of particle size and shape on the surface
specific dissolution rate of micronized practically insoluble drugs, Int. J. Pharm.
122 (1995) 35–47.[41] F. Kesisoglou, S. Panmai, Y. Wu, Nanosizing — oral formulation development and
biopharmaceutical evaluation, Adv. Drug Deliv. Rev. 5916 (2007) 31–44.
[42] A.A. Noyes, W.R. Whitney, The rate of solution of solid substances in their own
solutions, J. Am. Chem. Soc. 19 (1897) 930–934.
[43] M. Senna, S. Nakayama, Preparation and properties of nano-amorphous organic
and inorganic particles via chemical and mechanochemical routes, J. Alloys
Compd. 483 (2009) 265–270.
[44] R.S. Dhumal, S.V. Biradar, S. Yamamura, A.R. Paradkar, P. York, Preparation of
amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhance-
ment of bioavailability, Eur. J. Pharm. Biopharm. 70 (2008) 109–115.
[45] M.T. Crisp, C.J. Tucker, T.L. Rogers, R.O. Williams III, K.P. Johnston, Turbidimetric
measurement and prediction of dissolution rates of poorly soluble drug
nanocrystals, J. Control. Release 117 (2007) 351–359.
[46] F. Ishikawa, M. Murano, M. Hiraishi, T. Yamaguchi, I. Tamai, A. Tsuji, Insoluble
powder formulation as an effective nasal drug delivery system, Pharm. Res. 19
(2002) No. 8.
[47] N. Fransén, S. Bredenberg, E. Björk, Clinical study shows improved absorption of
desmopressin with novel formulation, Pharm. Res. 26 (2009) 1618–1625.
[48] N. Fransén, E. Björk, C. Nyström, Development and characterisation of interactive
mixtures with a fine-particulate mucoadhesive carrier for nasal drug delivery, Eur.
J. Pharm. Biopharm. 67 (2007) 370–376.
[49] F. Ishikawa, M. Katsura, I. Tamai, A. Tsuji, Improved nasal bioavailability of
elcatonin by insoluble powder formulation, Int. J. Pharm. 224 (2001) 105–114.
[50] W.A. Lee, B.A. Narog, T.W. Patapoff, Y.J. Wang, Intranasal bioavailability of insulin
powder formulations: effect of enhancer-to-protein ratio, J. Pharm. Sci. 80 (1991)
72–729.
[51] N.G.M. Schipper, S.G. Romejin, J.C. Verhoef, F.W.H.M. Merkus, Nasal insulin
delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits:
powder more effective than liquid formulations, Pharm. Res. 10 (1993) 682–686.
